Tools   Select Another Resource Report Type

http://www.mps-hamburg.com/

Full service Clinical Research Organization (CRO) in Hamburg, Germany, mainly focusing on phase-I and phase-IIa clinical trials. MPS owns 72 bed research clinic with 6 physicians and 15 nurses as permanent staff. MPS is experienced in performing all kind of early stage clinical trials, including first-in-man-trials, medical-devices-trials, nutraceutical and consumer-goods-trials. MPS holds active database of more than 17,000 healthy volunteers, plus hundreds of patients in special populations.

Proper citation: MPS Hamburg (RRID:SCR_004087) Copy   

•   Source: SciCrunch Registry

http://www.taros-discovery.com/

An independent contract research company that serves the needs of pharmaceutical, chemical, agrochemical and biotech companies, operating state-of-the art lab facilities and supporting the diverse needs of its customers in efficient drug discovery, medicinal chemistry and classical synthetic chemistry. Taros'' scientists combine more than 140 years industrial organic chemistry experience and over 60 years of active drug discovery experience from big pharmas and biotechs. They have expertise across a broad range of therapeutic areas (oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious) and in all small molecule target classes. They have developed TarosGate, a unique software suite putting cost, time and chemistry information at a Project Leader''s finger tips.

Proper citation: Taros (RRID:SCR_004119) Copy   

•   Source: SciCrunch Registry

http://www.syncom.nl/

Independent contract research organization / small and medium sized enterprise (CRO/SME) that assists pharma and biotechnology companies with medicinal chemistry programs, providing tailor-made custom synthesis solutions. Primary activities include synthesis of key building blocks, route scouting services, process research activities, scale up, medicinal chemistry services and hit-to-lead optimization. On custom basis they also synthesize metabolites, impurities, reference standards and stable labelled compounds. Their services are backed up by state-of-the-art analytical technologies such as HPLC, GC, LC-MS, GC-MS and NMR. These technologies can be offered as stand-alone analytical services as well. Syncom also has expertise in chiral technology. The firm has designed and synthesized numerous unique scaffolds, yielding many patent applications and clinical candidates. Name changed to Symeres after merger with Mercachem., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Syncom (RRID:SCR_004118) Copy   

•   Source: SciCrunch Registry

http://www.edelris.com/

A commercial medicinal chemistry company dedicated to the design and synthesis of natural product-mimetic screening compounds, Hit-to-Lead & Lead Optimization projects and Custom Synthesis. Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its validated chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit-to-lead optimization capabilities. EDELRIS has a wide range of services and based on its experience in various and complementary fields, the team is capable to deliver innovative solutions to synthetic and medicinal chemistry problems faced by clients.

Proper citation: Edelris (RRID:SCR_004112) Copy   

•   Source: SciCrunch Registry

http://www.idbs.com/

Commercial provider of advanced software and solutions that helps R&D teams make discoveries. They provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data. Their technology and domain expertise enables users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Their diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.

Proper citation: IDBS (RRID:SCR_004077) Copy   

•   Source: SciCrunch Registry

http://www.pivotparkscreeningcentre.com/

Commercial organization dedicated to open innovation, providing automated cellular and biochemical in-vitro screening experiments, and ultra-High Throughput Screening (uHTS) services. The Pivot Park facilities include MSD''s former screening centre which comprise two unique robotic systems for in-vitro screening. Because the new screening centre was able to retain a significant number of the original screening staff, it offers a wealth of experience in assay development, screening and automation in a new, open setting.

Proper citation: Pivot Park Screening Centre (RRID:SCR_004115) Copy   

•   Source: SciCrunch Registry

http://www.phenosys.com/

A research- and development-oriented company based in Berlin that engineers and markets technology for animal behavior research offering unique, automated instrumentation. This includes specialized applications of virtual reality and touch screen technology for animal behavior environments and RFID (transponder) operated devices in home cage environments. Their experimental systems are used for behavioral phenotyping, brain research, experimental psychology, and the diagnostic characterization of animal models for translational medicine.

Proper citation: PhenoSys (RRID:SCR_004072) Copy   

•   Source: SciCrunch Registry

http://www.kribb.re.kr/eng/main/main.jsp

Proper citation: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea (RRID:SCR_004071) Copy   

•   Source: SciCrunch Registry

http://www.noldus.com/

Commercial organization that develops tools and systems for measurement and analysis of animal and human behavior. They develop instrumented home cage systems, in which rodent behavior and ultrasonic vocalizations can be measured in a non-intrusive manner. Furthermore, they develop computer vision and pattern recognition technology for automated behavior detection. They believe that this approach has significant potential in research on animal models for Autism Spectrum Disorder.

Proper citation: Noldus (RRID:SCR_004074) Copy   

•   Source: SciCrunch Registry

http://iapo.org.uk/

A global alliance representing patients of all nations across all disease areas and promoting patient-centered healthcare across the world. They represent people who suffer from diseases, disabilities, illnesses, impairments or syndromes and work with communities of patients to get their voices heard by all involved in healthcare. With the help of their members and collaborating organizations, they work towards patient-centered healthcare throughout the world.

Proper citation: International Alliance of Patients Organizations (RRID:SCR_004073) Copy   

•   Source: SciCrunch Registry

http://www.kyoto-u.ac.jp/en

National university in Kyoto, Japan. It is the second oldest Japanese university, one of Asia highest ranked universities and one of Japan National Seven Universities.

Proper citation: Kyoto University; Kyoto; Japan (RRID:SCR_004108) Copy   

•   Source: SciCrunch Registry

https://www.bigtencrc.org/

A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center.

Proper citation: Big Ten Cancer Research Consortium (RRID:SCR_004025) Copy   

•   Source: SciCrunch Registry

http://www.asclepia.com/

Commercial organization that offers medicinal chemistry services and consulting consisting of the combination of structure based drug design and computational chemistry with multi-disciplinary expertise. A proven track record exists in the identification and the delivery of successful drug candidates. They offer solutions within small molecule drug discovery and outsourcing project management.

Proper citation: Asclepia MedChem Solutions (RRID:SCR_004023) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/OPB

A reference ontology of classical physics as applied to the dynamics of biological systems. It is designed to encompass the multiple structural scales (multiscale atoms to organisms) and multiple physical domains (multidomain fluid dynamics, chemical kinetics, particle diffusion, etc.) that are encountered in the study and analysis of biological organisms.

Proper citation: Ontology of Physics for Biology (RRID:SCR_004144) Copy   

•   Source: SciCrunch Registry

http://www.euadr-project.org/

Consortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect.

Proper citation: EU-ADR (RRID:SCR_004028) Copy   

•   Source: SciCrunch Registry

https://hoosiercancer.org/

An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member.

Proper citation: Hoosier Cancer Research Network (RRID:SCR_004026) Copy   

•   Source: SciCrunch Registry

http://danstem.ku.dk/

Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs.

Proper citation: DanStem (RRID:SCR_004021) Copy   

•   Source: SciCrunch Registry

http://www.mcewencentre.com/

Center aiming to be a catalyst for regenerative medicine by facilitating collaboration, supporting research, and promoting awareness of the field. The center includes 15 scientists at five Toronto hospitals, as well as the University of Toronto, currently working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. They collaborate with many other research institutions throughout North America, Europe and the Asia / Pacific region. The research is powered by a team of recent doctoral graduates recruited from around the world that are selected through a competitive process. They are a critical tool for supporting the work of McEwen Centre, allowing them to find medical breakthroughs faster.

Proper citation: McEwen Centre for Regenerative Medicine (RRID:SCR_004020) Copy   

•   Source: SciCrunch Registry

http://www.cclg.org.uk/index.php

THIS RESORUCE IS NO LONGER IN SERVICE. Documented on April 27,2023. CCLG is an association of healthcare professionals involved in the treatment and care of children and younger teenagers with cancer, and underpins all the activity in pediatric oncology in the British Isles. CCLG is committed to research and development in the treatment of cancer in this age group, the ultimate goal of which is to maximize cure while minimizing the early and late side effects of treatment. Provision of information for patients and families is a core activity. The Children''s Cancer and Leukaemia Group was formed in 2006 as a result of the merger of the UK Children''s Cancer Study Group and the UK Childhood Leukaemia Working Party, both of which had been in existence since the 1970s.

Proper citation: CCLG (RRID:SCR_004137) Copy   

•   Source: SciCrunch Registry

http://www.penta-id.org/

A Level 1 network for pediatric infectious disease in Europe recognized by the European networks of paediatric research at the European Medicines Agency (EnprEMA) whose activities vary from clinical trials, to cohort studies and training. It is currently developing a portfolio of clinical trials in antimicrobials in children, including antibiotics, antivirals and antifungals.

Proper citation: PENTA-ID (RRID:SCR_004092) Copy   

•   Source: SciCrunch Registry